DLBCL Education
DLBCL treatment has evolved with polatuzumab vedotin combinations, bispecific antibodies, and CAR-T cell therapy transforming outcomes in relapsed disease. Knowledge Med sessions help community providers navigate frontline and relapsed DLBCL through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing diffuse large b-cell lymphoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Optimizing frontline R-CHOP-based therapy with polatuzumab vedotin
- Identifying patients for early CAR-T cell therapy referral
- Integrating bispecific antibodies in relapsed/refractory disease
- Managing toxicities of novel agents including CRS and ICANS
What Sessions Cover
Knowledge Med DLBCL sessions use interactive case simulations to address these topics and more.
- Frontline DLBCL: pola-R-CHP and risk-adapted strategies
- Second-line therapy: CAR-T vs salvage chemotherapy and autologous SCT
- Bispecific antibodies in relapsed DLBCL: patient selection and monitoring
- Managing immune effector cell-associated toxicities
Interactive DLBCL Sessions
Case Simulations
Work through realistic diffuse large b-cell lymphoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key DLBCL clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Chronic Lymphocytic Leukemia
CLL / SLL — First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Myelodysplastic Syndromes
MDS — IPSS-M and molecular risk stratification in MDS
Join a DLBCL Session
Third-party, non-promotional diffuse large b-cell lymphoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session